FEATURES

Viewpoints

Circumcision May Reduce Prostate Cancer Risk

Circumcision May Reduce Prostate Cancer Risk

The evidence continues to grow that circumcision may help lower a man's overall risk for prostate cancer.

Topical Gel May Be as Effective as Oral Tamoxifen in DCIS

Topical Gel May Be as Effective as Oral Tamoxifen in DCIS

A topical gel containing an active metabolite of tamoxifen suppressed cell proliferation equally as well as the oral form.

Feature Articles

Palliative Care Integration and Expertise Are Pressing Goals for Oncologists

Palliative Care Integration and Expertise Are Pressing Goals for Oncologists

Two years after ASCO recommended an earlier integration of palliative care in standard cancer care, there is still more work to be done to ensure that palliative care is understood by both patients and their physicians and is effectively applied at the correct point within the cancer treatment process.

Oncologists Asked to Play Greater Role in Helping Obese Patients With Cancer

Oncologists Asked to Play Greater Role in Helping Obese Patients With Cancer

ASCO recommendation tasks oncologists with assisting obese patients with cancer in finding appropriate resources for weight management.

Helping Patients With Cancer Avoid Financial Toxicity

Helping Patients With Cancer Avoid Financial Toxicity

Cancer care costs are becoming a significant problem; however, a new tool may help oncologists assess how patients will be affected by treatment expenses.

Slideshows

PURIXAN® (mercaptopurine [6-MP] oral suspension)

PURIXAN® (mercaptopurine [6-MP] oral suspension)

This slideshow reviews drug information for PURIXAN® (mercaptopurine [6-MP] oral suspension), indicated for acute lymphoblastic leukemia.

Table of Contents

Slide 3: Indication, ...

SYLATRON® (peginterferon alfa-2b)

SYLATRON® (peginterferon alfa-2b)

Review slide-by-slide drug information for SYLATRON® (peginterferon alfa-2b) for treatment of melanoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 8: ...

From the Advisory Board

The Promise of PD-1/PD-L1 Antagonists in Treating Metastatic Melanoma

The Promise of PD-1/PD-L1 Antagonists in Treating Metastatic Melanoma

Mario Sznol, MD, comments on the results of his phase 1 study reporting on data from patients with metastatic melanoma treated with nivolumab.

CME

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.

CTA Community Poll

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs